Business
Premier Biomedical Inc., CEO William Hartman Returns to Uptick Newswire’s “Stock Day” with Everett Jolly
Premier Biomedical Inc., CEO William Hartman Returns to Uptick Newswire’s “Stock Day” with Everett Jolly.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n\n PHOENIX, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical Inc., (OTC:BIEI) President & CEO, William A. Hartman today reviewed operational accomplishments of 2017 and expectations for 2018 in an interview on Uptick Newswire’s “Stock Day” podcast with Everett Jolly.\n Premier Biomedical consists of two divisions, one focused on biologics and the other on topical pain relief products.  The pain relief division is revenue generating and has grown from one product a year ago, to five products today, distributed through the company’s website, www.painreliefmeds.com, and by a number of regional pharmacies and an on-line pharmacy, HealthWarehouse.com. “You have had impressive results from your cancer research,” said Jolly.  “Results that have been published by the American Association for Cancer Research as well as the British Journal of Cancer.  The company has also been able to grow the pain relief division significantly in only a year.” “We are proud of the work we have done in cancer research.  Recently, our Biologics Division has also focused on anti-aging, an industry worth over $1 billion in the United States alone,” Hartman commented.  “We are very optimistic regarding our work with anti-aging.  We have proven the ability to remove specific antigens from blood and have identified the antigens linked to aging.  We will continue to pursue this avenue, which has an incredible upside.” “On the pain relief front, we have made great strides in developing new, and highly effective products in 2017, and will concentrate on marketing and sales in 2018.” To listen to the full interview please click here to the following link: https://upticknewswire.com/featured-interview-ceo-william-hartman-of-premier-biomedical-inc-otcqb-biei-4 About Premier Biomedical Inc.Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis, Cancer and Anti-aging. We have developed an aggressive timetable to ad...